Skip to main content

Advertisement

SpringerLink
Log in

Long-term visual outcome and prognostic factors of Intravitreal anti-vascular endothelial growth factor treatment for retinal angiomatous proliferation

  • Retinal Disorders
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

To evaluate the long-term visual outcomes and investigate the prognostic factors of anti-vascular endothelial growth factor (VEGF) therapy for retinal angiomatous proliferation (RAP).

Methods

Thirty-eight treatment-naïve RAP eyes (38 patients) that received intravitreal anti-VEGF (ranibizumab and/or bevacizumab) injections were included and analyzed in this retrospective case series. All patients were treated with an initial series of three monthly intravitreal anti-VEGF injections, followed by as-needed injections for a total of 36 months.

Results

The mean number of anti-VEGF injections was 9.61 ± 3.1 during the 36-month follow-up. Mean baseline best-corrected visual acuity (BCVA) was 0.79 ± 0.56 logarithm of the minimum angle of resolution (logMAR; 20/123 Snellen equivalent), and 0.75 ± 0.41 logMAR (20/112 Snellen equivalent) at 36 months (P = 0.55). Mean BCVA significantly improved at 3 months (P = 0.001), and the significant improvement persisted until 18 months from baseline (P = 0.02). However, the mean BCVA between 18 and 36 months showed no statistical in comparison with baseline values. Geographic atrophy developed in 14 eyes (36.8 %) during the entire 36-month follow-up period. Among baseline characteristics, baseline BCVA, greatest lesion diameter (GLD), and lesion size were significantly correlated with long-term visual outcome (P = 0.008, 0.02, and 0.002 respectively).

Conclusions

Intravitreal anti-VEGF injections for RAP showed a favorable visual outcome during the first year; however, the visual gains declined after the second year from baseline. Better baseline BCVA, smaller lesion size, and smaller baseline GLD are associated with better long-term visual outcomes in patients with RAP.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Yannuzzi LA, Negrão S, Iida T et al (2001) Retinal angiomatous proliferation in age-related macular degeneration. Retina 21:416–434

    Article  PubMed  CAS  Google Scholar 

  2. Freund KB, Ho IV, Barbazetto IA et al (2008) Type 3 neovascularization: the expanded spectrum of retinal angiomatous proliferation. Retina 28:201–211

    Article  PubMed  Google Scholar 

  3. Gass JD, Agarwal A, Lavina AM, Tawansy KA (2003) Focal inner retinal hemorrhages in patients with drusen: an early sign of occult choroidal neovascularization and chorioretinal anastomosis. Retina 23:741–751

    Article  PubMed  Google Scholar 

  4. Maruko I, Iida T, Saito M, Nagayama D, Saito K (2007) Clinical characteristics of exudative age-related macular degeneration in Japanese patients. Am J Ophthalmol 144:15–22

    Article  PubMed  Google Scholar 

  5. Cohen SY, Creuzot-Garcher C, Darmon J et al (2007) Types of choroidal neovascularisation in newly diagnosed exudative age-related macular degeneration. Br J Ophthalmol 91:1173–1176

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  6. Bottoni F, Massacesi A, Cigada M, Viola F, Musicco I, Staurenghi G (2005) Treatment of retinal angiomatous proliferation in age-related macular degeneration: a series of 104 cases of retinal angiomatous proliferation. Arch Ophthalmol 123:1644–1650

    Article  PubMed  Google Scholar 

  7. Bressler NM (2005) Retinal anastomosis to choroidal neovascularization: a bum rap for a difficult disease. Arch Ophthalmol 123:1741–1743

    Article  PubMed  Google Scholar 

  8. Hartnett ME, Weiter JJ, Staurenghi G, Elsner AE (1996) Deep retinal vascular anomalous complexes in advanced age-related macular degeneration. Ophthalmology 103:2042–2053

    Article  PubMed  CAS  Google Scholar 

  9. Gharbiya M, Allievi F, Recupero V, Martini D, Mazzeo L, Gabrieli CB (2009) Intravitreal bevacizumab as primary treatment for retinal angiomatous proliferation: twelve-month results. Retina 29:740–749

    Article  PubMed  Google Scholar 

  10. Konstantinidis L, Mameletzi E, Mantel I, Pournaras JA, Zografos L, Ambresin A (2009) Intravitreal ranibizumab (Lucentis) in the treatment of retinal angiomatous proliferation (RAP). Graefes Arch Clin Exp Ophthalmol 247:1165–1171

    Article  PubMed  CAS  Google Scholar 

  11. Atmani K, Voigt M, Le Tien V et al (2010) Ranibizumab for retinal angiomatous proliferation in age-related macular degeneration. Eye (Lond) 24:1193–1198

    Article  CAS  Google Scholar 

  12. Parodi MB, Iacono P, Menchini F et al (2013) Intravitreal bevacizumab versus ranibizumab for the treatment of retinal angiomatous proliferation. Acta Ophthalmol 91:267–273

    Article  PubMed  CAS  Google Scholar 

  13. Hemeida TS, Keane PA, Dustin L, Sadda SR, Fawzi AA (2010) Long-term visual and anatomical outcomes following anti-VEGF monotherapy for retinal angiomatous proliferation. Br J Ophthalmol 94:701–705

    Article  PubMed  PubMed Central  Google Scholar 

  14. Rouvas AA, Chatziralli IP, Theodossiadis PG, Moschos MM, Kotsolis AI, Ladas ID (2012) Long-term results of intravitreal ranibizumab, intravitreal ranibizumab with photodynamic therapy, and intravitreal triamcinolone with photodynamic therapy for the treatment of retinal angiomatous proliferation. Retina 32:1181–1189

    Article  PubMed  CAS  Google Scholar 

  15. Boon CJ, van de Ven JP, Hoyng CB, den Hollander AI, Klevering BJ (2013) Cuticular drusen: stars in the sky. Prog Retin Eye Res 37:90–113

    Article  PubMed  Google Scholar 

  16. Lalwani GA, Rosenfeld PJ, Fung AE et al (2009) A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 148:43–58

    Article  PubMed  CAS  Google Scholar 

  17. Saito M, Iida T, Kano M (2012) Combined intravitreal ranibizumab and photodynamic therapy for retinal angiomatous proliferation. Am J Ophthalmol 153:504–514

    Article  PubMed  CAS  Google Scholar 

  18. Seidel G, Werner C, Weger M, Steinbrugger I, Haas A (2013) Combination treatment of photodynamic therapy with verteporfin and intravitreal ranibizumab in patients with retinal angiomatous proliferation. Acta Ophthalmol 91:482–485

    Article  CAS  Google Scholar 

  19. Kaiser PK, Brown DM, Zhang K et al (2007) Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthalmol 144:850–857

    Article  PubMed  CAS  Google Scholar 

  20. Rosenfeld PJ, Brown DM, Heier JS et al (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419–1431

    Article  PubMed  CAS  Google Scholar 

  21. Silva R, Axer-Siegel R, Eldem B et al (2013) The SECURE study: long-term safety of ranibizumab 0.5 mg in neovascular age-related macular degeneration. Ophthalmology 120:130–139

    Article  PubMed  Google Scholar 

  22. Martin DF, Maguire MG, Fine SL et al (2012) Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 119:1388–1398

    Article  PubMed  PubMed Central  Google Scholar 

  23. Grunwald JE, Daniel E, Huang J et al (2014) Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology 121:150–161

    Article  PubMed  PubMed Central  Google Scholar 

  24. Gharbiya M, Parisi F, Cruciani F, Bozzoni-Pantaleoni F, Pranno F, Abdolrahimzadeh S (2014) Intravitreal anti-vascular endothelial growth factor for retinal angiomatous proliferation in treatment-naive eyes: long-term functional and anatomical results using a modified PrONTO-style regimen. Retina 34:298–305

    Article  PubMed  CAS  Google Scholar 

  25. Viola F, Massacesi A, Orzalesi N, Ratiglia R, Staurenghi G (2009) Retinal angiomatous proliferation: natural history and progression of visual loss. Retina 29:732–739

    Article  PubMed  Google Scholar 

  26. Ying GS, Huang J, Maguire MG et al (2013) Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration. Ophthalmology 120:122–129

    Article  PubMed  PubMed Central  Google Scholar 

  27. Boyer DS, Antoszyk AN, Awh CC et al (2007) Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 114:246–252

    Article  PubMed  Google Scholar 

  28. McBain VA, Kumari R, Townend J, Lois N (2011) Geographic atrophy in retinal angiomatous proliferation. Retina 31:1043–1052

    Article  PubMed  Google Scholar 

  29. Kim JH, Kim JR, Kang SW, Kim SJ, Ha HS (2013) Thinner choroid and greater drusen extent in retinal angiomatous proliferation than in typical exudative age-related macular degeneration. Am J Ophthalmol 155:743–749

    Article  PubMed  Google Scholar 

Download references

Financial support

None.

Conflict of interest

The authors have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Ophthalmology, Kim’s Eye Hospital, Myung-Gok Eye Research Institute, Konyang University College of Medicine, 156, 4ga, Yeoungdeungpo-dong, Yeoungdeungpo-gu, Seoul, South Korea

    Han Joo Cho, Tae Gon Lee, Sang Youn Han, Hyoung Seok Kim, Jae Hui Kim, Jung Il Han, Young Ju Lew & Jong Woo Kim

Authors
  1. Han Joo Cho
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tae Gon Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sang Youn Han
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hyoung Seok Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jae Hui Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jung Il Han
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Young Ju Lew
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jong Woo Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tae Gon Lee.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cho, H.J., Lee, T.G., Han, S.Y. et al. Long-term visual outcome and prognostic factors of Intravitreal anti-vascular endothelial growth factor treatment for retinal angiomatous proliferation. Graefes Arch Clin Exp Ophthalmol 254, 23–30 (2016). https://doi.org/10.1007/s00417-015-2993-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-015-2993-3

Keywords

Search

Navigation